Erratum: Endogenous immune response to gangliosides in patients with confined prostate cance (International Journal of Cancer (2015) 116:3 (368-377) DOI: 10.1002/ijc.21023);Endogenous immune response to gangliosides in patients with confined prostate cancer

International Journal of Cancer

Volumn 116, Issue 3, 2005, Pages 368-377

  Ravindranath, Mepur H ^a   Muthugounder, Sakunthala ^a   Presser, Naftali ^a   Ye, Xing ^a   Brosman, Stanley ^b   Morton, Donald L ^a  

^a JOHN WAYNE CANCER INSTITUTE   (United States)

^b Pacific Clinical Research   (United States)

Author keywords

Antiganglioside IgM; Benign prostatic hyperplasia; Endogenous immune response; Organ confined prostate cancer; Tumor associated gangliosides

Indexed keywords

GANGLIOSIDE; GANGLIOSIDE GD 1A; GANGLIOSIDE GD 1B; GANGLIOSIDE GD2; GANGLIOSIDE GD3; GANGLIOSIDE GM2; GANGLIOSIDE GM3; GANGLIOSIDE GT 1B; IMMUNOGLOBULIN M ANTIBODY; RESORCINOL;

ADULT; AGED; ANALYSIS OF VARIANCE; ANTIBODY TITER; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; HUMAN CELL; IMMUNE RESPONSE; MALE; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATE EPITHELIUM; PROSTATE HYPERTROPHY;

EID: 22244451334     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.29255     Document Type: Erratum

References (64)

1. Ravindranath MH, Morton DL. Immunogenicity of membrane-bound gangliosides in viable whole-cell vaccines. Cancer Invest 1997;15: 491-9.
2. Ravindranath MH, Tsuchida T, Morton DL, Irie RF. Ganglioside GM3: GD3 ratio as an index for the management of melanoma. Cancer 1991;67:3029-35.
3. Tsuchida T, Saxton RE, Morton DL, Irie RF. Gangliosides of human melanoma. J Natl Cancer Inst 1987;78:45-54.
4. Carubia JM, Yu KK, Macala LJ, Kirkwood JM, Varga JM. Gangliosides of normal and neoplastic human melanocytes. Biochem Biophys Res Commun 1984;120:500-4.
5. Chu KU, Ravindranath MH, Gonzales A, Nishimoto K, Tam WT, Soh D, Bilchik A, Katopodis N, Morton DL. Gangliosides as targets for immunotherapy for pancreatic adenocarcinoma. Cancer 2000;88: 1828-36.
6. Ferroni P, Lenti L, Guadagni F, Matini F, D'Agostino F, Spila A, Pontieri GM, Gazzaniga PP. Possible involvement of tumour cell membrane gangliosides in platelet-tumour cell interactions. Eur J Cancer 1995;31A:79-84.
7. Ravindranath MH, Morton DL. Antigens: carbohydrates. In: Encyclopedia of life sciences. London: MacMillan, 2000.
8. Shiraishi T, Kinter MT, Mills SE, Lippert MC, Bova GS, Young WW Jr. The glycosphingolipids of human prostate tissue. Biochim Biophys Acta 1988;961:164-9.
9. Satoh M, Fukush, Y, Kawamura S, Ohyama C, Saito S, Orikasa S, Nudleman E, Hakamori S. Glycolipid expression in prostatic tissue and analysis of the antigen recognized by antiprostatic monoclonal antibody APG1. Urol Int 1992;48:20-4.
10. Zhang S, Zhang HS, Reuter VE, Slovin SF, Scher HI, Livingston PO. Expression of potential target antigens for immunotherapy on primary and metastatic prostate cancers. Clin Cancer Res 1998;4:295-302.
11. Kong Y, Li R, Ladisch S. Natural forms of shed tumor gangliosides. Biochim Biophys Acta 1998;1394:43-56.
12. Hakansson L, Fredman P, Svennerholm L. Gangliosides in serum immune complexes from tumor-bearing patients. J Biochem 1985;98:843-9.
13. Valentino LA, Ladisch S. Localization of shed human tumor gangliosides: association with lipoproteins. Cancer Res 1992;52:810-4.
14. Dolo V, Li R, Dillinger M, Flati S, Manela J, Taylor BJ, Pavan A, Ladisch S. Enrichment and localization of ganglioside G(D3) and caveolin-1 in shed tumor cell membrane vesicles. Biochim Biophys Acta 2000;1486:265-74.
15. Ravindranath MH, Hsueh EC, Verma M, Ye W, Morton DL. Serum total ganglioside level correlates with clinical course in melanoma patients after immunotherapy with therapeutic cancer vaccine. J Immunother 2003;26:277-85.
16. Ravindranath MH, Wood TF, Soh D, Gonzales A, Muthugounder S, Perez C, Morton DL, Bilchik A. Cryosurgical ablation of liver tumors in colon cancer patients increases the serum total ganglioside level and then selectively augments antiganglioside IgM. Cryobiology 2002;45:10-21.
17. Ravindranath MH, Gonzales AM, Nishimoto K, Tam WY, Soh D, Morton DL. Immunology of gangliosides. Ind J Exp Biol 2000;38: 301-12.
18. Perez CA, Ravindranath MH, Soh D, Gonzales A, Ye W, Morton DL. Serum antiganglioside IgM antibodies in soft tissue sarcoma: clinical prognostic implications. Cancer J 2002;8:384-94.
19. Ravindranath MH, Muthugounder S, Presser N, Selvan SR, Portoukalian J, Brosman S, Morton DL. Gangliosides of organ-confined versus metastatic androgen-receptor-negative prostate cancer. Biochem Biophys Res Commun 2004;324:154-65.
20. Ravindranath MH, Ravindranath RMH, Morton DL, Graves MC. Factors affecting the fine specificity and sensitivity of serum anti-ganglioside antibodies in ELISA. J Immunol Methods 1994;169:257-72.
21. Svennerholm L. Quantitative estimation of sialic acid. II. Acolorimetric resorcinol-hydrochloric acid method. Biochim Biophys Acta 1957; 24:604-11.
22. Ravindranath MH. Bauer PM, Cornillez-Ty C, Garcia J, Morton DL. Quantitation of the density of cell-surface carbohydrate antigens on cancer cells with a sensitive cell-suspension ELISA. J Immunol Methods 1996;197:51-67.
23. Ravindranath MH, Amiri AA, Bauer PM. A sensitive cell suspension ELISA [cs-ELISA] for measuring the density of cell-surface ganglioside and carbohydrate antigens. In: Townsend R. Techniques in glycobiology. New York: Marcel Dekker, 1997. 137-65.
24. Cabot MC. Ceramide glycosylation and chemotherapy resistance. In: Futerman AH. Ceramide signaling. New York: Kluwer Academic, 2002. 133-9.
25. Lavie Y, Cao H, Volner A, Lucci A, Han TY, Geffen V, Giuliano AE, Cabot MC. Agents that reverse multidrug resistance, tamoxifen, verapamil, and cyclosporine A, block glycosphingolipid metabolism by inhibiting ceramide glycosylation in human cancer cells. J Biol Chem 1997;272:1682-7.
26. Liu YY, Han TY, Giuliano AE, Cabot MC. Expression of glucosylceramide synthase, converting ceramide to glucosylceramide, confers adriamycin resistance in human breast cancer cells. J Biol Chem 1999;274:1140-6.
27. Liu YY, Han TY, Giuliano AE, Cabot MC. Ceramide glycosylation potentiates cellular multidrug resistance. FASEB J 2001;15:719-30.
28. Bergelson LD. Serum gangliosides as endogenous immuno-modulators. Immunol Today 1995;46:483-6.
29. Matzinger P. The danger model: a renewed sense of self. Science 2002;296:301-5.
30. Matzinger P. An innate sense of danger. Ann NY Acad Sci 2002;961: 341-2.
31. Tsuchida T, Ravindranath MH, Saxton RE, Irie RF. Gangliosides of human melanoma: altered expression in vivo and in vitro. Cancer Res 1987;47:1278-81.
32. Freimer ML, McIntosh K, Adams RA, Alving CR, Drachman DB. Gangliosides elicit a T-cell independent antibody response. J Autoimmun 1993;6:281-9.
33. Ravindranath MH, Gonzales A, Soh D, Nishimoto K, Tam WY, Bilchik A, Morton DL, O'Day S. Interleukin-2 binds to ganglioside GD1b. Biochem Biophys Res Commun 2001;283:369-73.
34. Kaucic K, Grovas A, Li R, Quinones R, Ladisch S. Modulation of human myelopoiesis by human gangliosides. Exp Hematol 1994;22: 52-9.
35. Kanda N. Gangliosides GD1a and GM3 induce interleukin-10 production by human T cells. Biochem Biophys Res Commun 1999;256: 41-4.
36. Shen W, Ladisch S. Ganglioside GD1a impedes lipopolysaccharide-induced maturation of human dendritic cells. Cell Immunol 2002;220: 125-33.
37. Caldwell S, Heitger A, Shen W, Liu Y, Taylor B, Ladisch S. Mechanisms of ganglioside inhibition of APC function. J Immunol 2003; 171:1676-83.
38. Rayman P, Wesa AK, Richmond AL, Das T, Biswas K, Raval G, Stork WJ, Tannenbaum C, Novick A, Bukowski R, Finke J. Effect of renal cell carcinomas on the development of type 1 T responses. Clin Cancer Res 2004;10:6360S-6S.
39. Lang Z, Guerrera M, Li R, Ladisch S. Ganglioside GD1a enhances VEGF-induced endothelial cell proliferation and migration. Biochem Biophys Res Commun 2001;282:1031-7.
40. Tai T, Cahan LD, Paulson JC, Saxton RE, Irie RF. Immunogenicity of melanoma-associated gangliosides in cancer patients. Int J Cancer 1984;35:607-12.
41. Morton DL, Ravindranath MH, Irie RF. Tumor gangliosides as targets for active specific immunotherapy of melanoma in man. Brain Res 1994;101:251-75.
42. Hakomori S. Tumor-associated carbohydrate antigens defining tumor malignancy: basis for development of anti-cancer vaccines. Adv Exp Med Biol 2001;491:369-402.
43. Helling F, Zhang S, Shang A, Adluri S, Calves M, Koganty R, Longenecker BM, Yao TJ, Oettgen HF, Livingston PO. GM2-KLH conjugate vaccine: increased immunogenicity in melanoma patients after administration with immunological adjuvant QS-21. Cancer Res 1995;55:2783-8.
44. Irie RF, Morton DL. Regression of cutaneous metastatic melanoma by intralesional injection with human monoclonal antibody to ganglioside GD2. Proc Natl Acad Sci USA 1986;83:8694-8.
45. Nakamura K, Tanaka Y, Shitara K, Hanai N. Construction of humanized anti-ganglioside monoclonal antibodies with potent immune effector functions. Cancer Immunol Immunother 2001;50: 275-84.
46. Raffaghello L, Marimpietri D, Pagnan G, Pastorino F, Cosimo E, Brignole C, Ponzoni M, Montaldo PG. Anti-GD2 monoclonal antibody immunotherapy: a promising strategy in the prevention of neuroblastoma relapse. Cancer Lett 2003;197:205-9.
47. Morton DL, Hsueh EC, Essner R, Foshag LJ, O'Day SJ, Bilchik A, Gupta R, Hoon DSB, Ravindranath M, Nizze JA, Gammon G, Wanek LA, et al. Prolonged survival of patients receiving active immunotherapy with Canvaxin therapeutic polyvalent vaccine after complete resection of melanoma metastatic to regional lymph nodes. Ann Surg 2002;236:438-49.
48. Berra B, Papi L, Bigozzi U, Serino D, Morichi R, Mennonna P, Rapelli R, Cogiliati T, Montali E. Correlation between cytogenetic data and ganglioside pattern in human menigiomas. Int J Cancer 1991;47:329-33.
49. Ariga T, Bhat S, Kanda T, Yamawaki M, Tai T, Kushi Y, Kasama T, Handa S, Yu RK. Expression and localization of Lewis (x) glycolipids and GD1a ganglioside in glioma cells. Glycoconj J 1996;13: 135-45.
50. Chang F, Li R, Noon K, Gage D, Ladisch S. Human medulloblastoma gangliosides. Glycobiology 1997;7:523-30.
51. Yates AJ, Franklin TK, McKinney P, Collins R, Comas T, Boesel CP, Pearl DK. Gangliosides and neutral glycolipids in ependymal, neuronal and primitive neuroectodermal tumors. J Mol Neurosci 1999;12: 111-21.
52. Anh-Tuan, N, Pick J, Mod A, Hollan SR. Gangliosides in acute myeloid leukemia (AML) and non-Hodgekin's lymphoma (NHL). Eur J Cancer Clin Oncol 1986;22:1003-7.
53. Ugorski M, Pahlsson P, Dus D, Nilsson B, Radzikowski C. Glycosphingolipids of human urothelial cell lines with different grades of transformation. Glycoconj J 1989;6:303-18.
54. Mariano A, Di Carlo A, Macchia PE, Pisano G, Parmeggiani U, Macch V. Gangliosides and phospholipids in human thyroids responsive and unresponsive to thyrotropin. J Endocrinol Invest 1990;13: 817-23.
55. Hoon DS, Okun E, Neuwirth H, Morton DL, We RF. Aberrant expression of gangliosides in human renal cell carcinomas. J Urol 1993;150:2013-8.
56. Nohara K, Wang F, Spiegel S. Glycosphingolipid composition of MDA-MB-231 and MCF-7 human breast cancer cell lines. Breast Cancer Res Treat 1998;48:149-57.
57. Hakansson L, Fredman P, Svennerholm L. Gangliosides in serum immune complexes from tumor-bearing patients. J. Biochem (Tokyo) 1985;98:843-9.
58. Dotta F, Colman PG, Lombardi D, Scharp DW, Andreani D, Pontieri C, Di Mario U, Lenti L, Eisenbarth GS, Nayak RC. Ganglioside expression human pancreatic islets. Diabetes 1989;38:1478-83.
59. Mukhin DN, Prokazova NV, Bergelson LD, Orekhov AN. Ganglioside content and composition of cells from normal and atherosclerotic human aorta. Atherosclerosis 1989;78:39-45.
60. Zhu Z, Deng H, Fenderson BA, Nudelman ED, Tsui Z. Glycosphingolipids of human myometrium and endometrium: their changes during the menstrual cycle, pregnancy and aging. J Reprod Fertil 1990; 88:71-9.
61. Muthing J, Cacic M. Glycosphingolipid expression in human skeletal and heart muscles assessed by immunostaining thin-layer chromatography. Glycoconj J 1997;14:19-28.
62. Natomi H, Saitoh T, Sugano K, Iwamori M, Fukayama M, Nagai Y. Systematic analysis of glycosphingolipids in the human gastrointestinal tract: enrichment of sulfatides with hydroxylated longer-chain fatty acids in the gastric and duodenal mucosa. Lipids 1993;28:737-42.
63. Ogiso M, Saito N, Sudo K, Kubo H, Hirano S, Komoto M. Increase in lens gangliosides due to aging and cataract progression in human senile cataract. Invest Ophthalmol Vis Sci 1990;31: 2171-9.
64. Kanda N, Watanabe S. Ganglioside GD1a enhances immunoglobulin production by human peripheral blood mononuclear cells. Exp Hematol 2000;672-9.